StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
444
This month
4
This week
1
This year
27
Publishing Date
2023 - 11 - 22
3
2023 - 10 - 16
3
2023 - 10 - 11
3
2023 - 05 - 08
4
2023 - 04 - 20
3
2023 - 04 - 18
3
2023 - 01 - 10
2
2023 - 01 - 09
2
2023 - 01 - 06
2
2022 - 12 - 15
2
2022 - 12 - 09
2
2022 - 12 - 05
2
2022 - 11 - 28
2
2022 - 11 - 07
3
2022 - 10 - 31
2
2022 - 10 - 10
2
2022 - 10 - 03
4
2022 - 09 - 05
2
2022 - 08 - 24
2
2022 - 08 - 08
2
2022 - 07 - 19
5
2022 - 07 - 05
2
2022 - 06 - 14
3
2022 - 06 - 13
5
2022 - 06 - 06
4
2022 - 05 - 16
2
2022 - 05 - 05
2
2022 - 04 - 06
2
2022 - 03 - 14
2
2022 - 03 - 01
3
2022 - 02 - 28
2
2022 - 02 - 14
2
2022 - 01 - 25
2
2021 - 12 - 24
2
2021 - 12 - 13
2
2021 - 11 - 22
2
2021 - 11 - 04
3
2021 - 11 - 02
3
2021 - 10 - 28
2
2021 - 09 - 30
2
2021 - 09 - 27
3
2021 - 09 - 24
2
2021 - 09 - 23
2
2021 - 09 - 18
2
2021 - 09 - 17
2
2021 - 09 - 02
2
2021 - 08 - 16
2
2021 - 08 - 05
2
2021 - 08 - 03
2
2021 - 07 - 26
2
2021 - 07 - 16
3
2021 - 07 - 14
2
2021 - 07 - 09
2
2021 - 06 - 25
2
2021 - 05 - 05
3
2021 - 04 - 23
4
2021 - 04 - 20
2
2021 - 04 - 19
2
2021 - 04 - 13
2
2021 - 03 - 16
2
Sector
Administrative and support and waste management and remediation services
1
Consumer services
2
Electronic technology
1
Finance
4
Health services
2
Health technology
444
Manufacturing
14
N/a
6
Professional, scientific, and technical services
9
Technology services
1
Tags
Alliances
9
Antibody
18
Application
17
Approval
41
Asco
7
Asia
8
Atopic dermatitis
9
Baricitinib
9
Biocapital
37
Business
8
Cancer
57
Car-t
11
Cel
9
Cell
11
Cell carcinoma
7
China
33
Chinese
25
Clinical-trials-phase-iii
12
Collaboration
19
Companies
24
Dermatitis
11
Designation
15
Disease
16
Drug
33
Earnings
21
Events
17
Expected
9
Fda
23
Financial
21
Financial results
13
Granted
7
Growth
34
Ibi351
9
Ibi362
12
Market
54
Medical
8
Meeting
16
N/a
279
New drug
9
Obesity
10
Pancreatic
7
People
10
Phase 1
14
Phase 2
19
Phase 3
23
Positive
15
Presentation
11
Report
13
Research
19
Results
72
Review
8
Study
37
T-cell
11
Therapeutics
20
Therapy
37
Treatment
77
Trial
28
Tumors
8
Tyvyt
9
Update
12
Entities
Abbvie inc.
17
Acadia pharmaceuticals inc.
4
Adc therapeutics sa
13
Agenus inc.
3
Agios pharmaceuticals, inc.
11
Alkermes plc
5
Alnylam pharmaceuticals, inc.
14
Alpine immune sciences, inc.
3
Amgen inc.
12
Arcus biosciences, inc.
4
Astellas pharma inc
6
Astrazeneca plc
3
Athenex, inc.
3
Atreca, inc.
3
Aveo pharmaceuticals, inc.
18
Beigene, ltd.
12
Biogen inc.
4
Biomea fusion inc
3
Biontech se
6
Blueprint medicines corporation
23
Briacell therapeutics corp.
4
Bristol-myers squibb company
24
Cellectis s.a.
3
Clovis oncology, inc.
19
Eli lilly and company
207
Epizyme, inc.
21
Exelixis, inc.
14
Glaxosmithkline plc
7
Global blood therapeutics, inc.
5
Illumina, inc.
10
Incyte corporation
444
Ionis pharmaceuticals, inc.
7
Iovance biotherapeutics, inc.
5
Ironwood pharmaceuticals, inc.
4
Jazz pharmaceuticals plc
5
Johnson & johnson
22
Karyopharm therapeutics inc.
18
Leap therapeutics, inc.
4
Macrogenics, inc.
11
Merus n.v.
14
Morphosys ag
28
Neurocrine biosciences, inc.
4
Novartis ag
21
Pfizer, inc.
14
Ptc therapeutics, inc.
4
Regeneron pharmaceuticals, inc.
18
Rigel pharmaceuticals, inc.
10
Sage therapeutics, inc.
4
Sanofi
121
Sarepta therapeutics, inc.
4
Seagen inc.
4
Syndax pharmaceuticals, inc.
5
Syros pharmaceuticals, inc.
11
Takeda pharmaceutical company limited
16
Ultragenyx pharmaceutical inc.
6
United therapeutics corporation
4
Urogen pharma ltd.
4
Verastem, inc.
10
Xencor, inc.
37
Y-mabs therapeutics, inc.
18
Symbols
AAPL
1194
ABB
1423
ABBV
1023
ABLZF
1162
ABT
1784
ACN
600
AMGN
742
ARVL
4285
AZN
664
BDX
796
BMY
662
BNPQF
1764
BNPQY
1764
CSCO
896
DHR
785
ERIC
1608
F
641
FNCTF
7171
FRBA
595
GE
915
GLAXF
657
GOOG
1274
GOOGL
1273
GSK
883
HON
1779
HUBS
1400
IBM
654
INTC
954
IT
590
JNJ
4571
LLY
1708
LTUM
970
LYV
717
MDT
1285
MMM
938
MS
4281
MSFT
1199
MT
588
NOC
589
NOK
899
NOKBF
973
NVO
631
NVS
1241
NVSEF
1031
ORCL
1157
PCRFF
650
PCRFY
650
PFE
692
PHG
962
PPRUF
1126
PPRUY
1127
SAP
1474
SAPGF
1228
SNOW
794
SNY
4532
SNYNF
3590
TEVJF
630
TMO
1621
VZ
1211
XYF
674
Exchanges
Amex
2
Nasdaq
444
Nyse
269
Crawled Date
2023 - 11 - 22
3
2023 - 10 - 16
3
2023 - 10 - 11
3
2023 - 05 - 08
4
2023 - 04 - 20
3
2023 - 04 - 18
3
2022 - 12 - 05
2
2022 - 11 - 28
2
2022 - 11 - 07
3
2022 - 10 - 31
2
2022 - 10 - 10
2
2022 - 10 - 03
4
2022 - 09 - 05
2
2022 - 08 - 24
2
2022 - 08 - 08
2
2022 - 07 - 20
2
2022 - 07 - 19
4
2022 - 07 - 05
2
2022 - 06 - 29
2
2022 - 06 - 14
3
2022 - 06 - 13
5
2022 - 06 - 06
4
2022 - 05 - 16
2
2022 - 05 - 05
2
2022 - 04 - 06
2
2022 - 03 - 14
2
2022 - 03 - 01
3
2022 - 02 - 28
2
2022 - 02 - 24
2
2022 - 02 - 14
2
2022 - 01 - 26
2
2021 - 12 - 24
2
2021 - 12 - 13
2
2021 - 11 - 22
2
2021 - 11 - 04
3
2021 - 11 - 02
3
2021 - 10 - 28
2
2021 - 09 - 30
2
2021 - 09 - 27
3
2021 - 09 - 24
2
2021 - 09 - 23
2
2021 - 09 - 22
2
2021 - 09 - 18
2
2021 - 09 - 17
2
2021 - 09 - 02
2
2021 - 08 - 16
2
2021 - 08 - 05
2
2021 - 08 - 03
2
2021 - 07 - 26
2
2021 - 07 - 16
3
2021 - 07 - 14
2
2021 - 07 - 09
2
2021 - 06 - 25
2
2021 - 06 - 02
2
2021 - 05 - 05
3
2021 - 04 - 23
4
2021 - 04 - 20
2
2021 - 04 - 19
2
2021 - 04 - 13
2
2021 - 03 - 16
2
Crawled Time
00:00
42
00:01
1
00:20
6
01:00
73
02:00
4
03:00
6
04:20
3
05:00
4
06:00
4
07:00
3
09:00
7
10:00
5
11:00
12
11:36
1
12:00
26
12:09
1
12:15
4
12:20
3
12:30
4
13:00
18
13:13
1
13:15
3
13:20
2
13:30
7
13:50
1
14:00
13
14:15
2
14:20
5
14:30
2
14:58
1
15:00
15
15:15
1
15:20
1
15:30
2
16:00
28
16:20
1
17:00
16
17:37
1
18:00
11
18:04
1
18:17
1
18:26
1
18:31
2
18:33
1
18:40
1
18:42
1
19:00
8
19:11
2
19:32
1
19:52
1
20:00
11
20:59
1
21:00
36
22:00
23
23:00
13
Source
investor.alkermes.com
4
mindmed.co
2
www.biospace.com
165
www.fda.gov
18
www.globenewswire.com
25
www.precisionbiosciences.com
1
www.preludetx.com
1
www.prnewswire.com
228
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
symbols :
INCY
save search
Metastatic Pancreatic Cancer Market to Proliferate Immensly, Predicts DelveInsight | Key Companies to Look Out for - FibroGen, AstraZeneca, Jiangsu HengRui, ImmunityBio, SynerGene, Mirati, Incyte, Astellas, AbbVie, Cue Biopharma, PureTech
Published:
2023-06-15
(Crawled : 15:00)
- prnewswire.com
ALPMY
|
News
|
$9.34
-1.11%
690K
|
Manufacturing
|
-42.8%
|
O:
-0.92%
H:
0.0%
C:
-0.37%
BMEA
|
$11.5
-3.77%
-3.91%
700K
|
Professional, Scientific, and T...
|
-69.28%
|
O:
-0.15%
H:
0.0%
C:
-5.2%
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
67.69%
|
O:
0.06%
H:
1.91%
C:
1.32%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-14.19%
|
O:
-0.11%
H:
2.08%
C:
1.97%
companies
cue
cancer
pancreatic
market
Immune Checkpoint Inhibitors Market to Grow at a Substantial Growth Rate, Predicts DelveInsight | Key Companies in the Market - Regeneron, GlaxoSmithKline, Roche, Boehringer Ingelheim, AstraZeneca, Seagen, Roche
Published:
2023-06-13
(Crawled : 15:00)
- prnewswire.com
SNYNF
|
News
|
$92.116
-2.18%
2.3K
|
Health Technology
|
-10.22%
|
O:
-1.21%
H:
0.0%
C:
-1.27%
ALPMY
|
News
|
$9.34
-1.11%
690K
|
Manufacturing
|
-42.91%
|
O:
1.71%
H:
0.0%
C:
-1.32%
XNCR
|
$19.08
0.85%
0.84%
450K
|
Health Technology
|
-29.68%
|
O:
0.22%
H:
0.69%
C:
0.04%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-9.94%
|
O:
-0.92%
H:
0.32%
C:
-0.41%
NXTC
|
$1.51
-7.93%
-8.61%
120K
|
Health Technology
|
-9.58%
|
O:
-2.99%
H:
4.32%
C:
1.85%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-15.1%
|
O:
-0.48%
H:
1.44%
C:
0.24%
BNTX
|
$86.42
0.09%
0.09%
1.2M
|
Health Technology
|
-21.36%
|
O:
0.18%
H:
5.8%
C:
5.1%
companies
roche
growth
market
Alkermes Issues Letter to Shareholders Highlighting Skills and Experience of Refreshed Board of Directors
Published:
2023-06-13
(Crawled : 11:00)
- investor.alkermes.com
ENDPQ
|
$0.004
-50.0%
1.7M
|
n/a
|
-92.45%
|
O:
-47.17%
H:
110.71%
C:
96.43%
IRM
|
$75.15
0.59%
0.0%
1.2M
|
Finance
|
33.32%
|
O:
-0.18%
H:
0.94%
C:
0.2%
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
68.59%
|
O:
-0.37%
H:
0.84%
C:
0.46%
AMRX
|
$5.46
0.18%
0.18%
1.2M
|
Health Technology
|
116.27%
|
O:
0.4%
H:
8.7%
C:
1.98%
ZLAB
|
$13.75
-4.65%
-4.87%
400K
|
Health Technology
|
-50.34%
|
O:
0.94%
H:
0.0%
C:
-0.93%
VRTX
|
$393.1
-0.27%
-0.27%
880K
|
Health Technology
|
15.41%
|
O:
0.08%
H:
1.04%
C:
0.36%
UTHR
|
$235.44
1.58%
1.55%
370K
|
Health Technology
|
3.25%
|
O:
-0.65%
H:
2.13%
C:
1.37%
RARE
|
$44.11
4.25%
4.08%
890K
|
Health Technology
|
-14.18%
|
O:
0.72%
H:
2.22%
C:
0.5%
SRPT
|
$117.885
0.51%
0.48%
550K
|
Health Technology
|
-9.36%
|
O:
0.55%
H:
2.23%
C:
-0.71%
SAGE
|
News
|
$12.585
-19.48%
-24.2%
4.3M
|
Health Technology
|
-78.2%
|
O:
0.07%
H:
2.89%
C:
1.85%
PTCT
|
News
|
$25.19
-0.4%
-0.4%
670K
|
Health Technology
|
-41.96%
|
O:
-0.3%
H:
2.48%
C:
1.97%
PRTA
4
|
$21.03
-1.45%
-1.47%
460K
|
Health Technology
|
-71.24%
|
O:
0.29%
H:
5.34%
C:
4.38%
NBIX
M
|
$133.26
0.2%
0.2%
570K
|
Health Technology
|
42.51%
|
O:
0.05%
H:
2.35%
C:
2.29%
MDXG
|
$6.335
1.69%
1.66%
870K
|
Health Technology
|
7.29%
|
O:
0.85%
H:
1.34%
C:
-0.17%
LPTX
|
$2.96
-0.67%
-0.68%
150K
|
Health Technology
|
-54.87%
|
O:
0.0%
H:
9.63%
C:
9.63%
JAZZ
|
News
|
$107.15
-1.61%
-1.63%
590K
|
Health Technology
|
-14.74%
|
O:
-0.02%
H:
1.93%
C:
1.16%
IRWD
|
$7.66
-2.92%
-3.0%
2.4M
|
Health Technology
|
-33.01%
|
O:
0.0%
H:
0.35%
C:
-3.42%
IONS
|
$40.93
-1.47%
-1.49%
1.1M
|
Health Technology
|
-1.73%
|
O:
0.17%
H:
1.25%
C:
0.46%
INFI
|
$0.016
12.5%
1.1M
|
Health Technology
|
-91.05%
|
O:
0.0%
H:
0.0%
C:
-5.76%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-15.1%
|
O:
-0.48%
H:
1.44%
C:
0.24%
IDXX
|
$478.04
-2.36%
-2.41%
530K
|
Health Technology
|
3.86%
|
O:
0.31%
H:
1.9%
C:
1.42%
EXEL
|
$22.875
0.24%
0.24%
2.8M
|
Health Technology
|
20.61%
|
O:
0.05%
H:
0.89%
C:
0.52%
CYCN
|
$3.18
12.62%
440
|
Health Technology
|
-26.9%
|
O:
6.44%
H:
0.41%
C:
-1.94%
BPMC
|
$88.395
2.68%
2.61%
730K
|
Health Technology
|
49.38%
|
O:
0.62%
H:
2.47%
C:
0.53%
AXLA
|
$4.58
-56.33%
42K
|
Health Technology
|
1377.42%
|
O:
-1.06%
H:
6.94%
C:
-2.15%
ALNY
|
$145.23
-1.02%
-1.03%
500K
|
Health Technology
|
-24.01%
|
O:
0.07%
H:
2.64%
C:
2.23%
ALKS
|
News
|
$24.05
1.18%
1.16%
2.3M
|
Health Technology
|
-22.74%
|
O:
0.19%
H:
1.58%
C:
0.64%
ACAD
|
News
|
$17.2
0.7%
0.7%
1M
|
Health Technology
|
-30.07%
|
O:
0.12%
H:
1.83%
C:
1.58%
IBIO
|
$1.89
-3.08%
0.0%
270K
|
Health Technology
|
159.44%
|
O:
16.68%
H:
3.53%
C:
-11.59%
Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board
Published:
2023-06-12
(Crawled : 20:00)
- globenewswire.com
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-15.1%
|
O:
-0.48%
H:
1.44%
C:
0.24%
GLPG
|
News
|
$29.25
-0.81%
-0.82%
190K
|
Health Technology
|
-30.82%
|
O:
-0.92%
H:
1.29%
C:
0.55%
Innovent Announces Phase 1 Clinical Data of IBI322 (CD47/PD-L1 Bispecific Antibody) in the Treatment of Anti-PD-(L)1-resistant Classic Hodgkin Lymphoma Patients at the EHA 2023 Annual Meeting
Published:
2023-06-12
(Crawled : 00:00)
- prnewswire.com
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
68.32%
|
O:
0.02%
H:
0.19%
C:
-0.19%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-9.91%
|
O:
0.04%
H:
0.0%
C:
0.0%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-13.63%
|
O:
0.2%
H:
1.57%
C:
1.54%
ibi322
treatment
meeting
Renal Cell Carcinoma Market to Witness Upsurge in Growth, Assesses DelveInsight | Key Companies Active in the Treatment Segment - MedImmune, CRISPR, Merck, Daiichi Sankyo, Exelixis, Xencor, SOTIO, Arcus, Pfizer, Roche, AstraZeneca
Published:
2023-06-08
(Crawled : 15:00)
- prnewswire.com
RCUS
4
|
$14.84
-6.49%
0.0%
790K
|
Health Technology
|
-27.89%
|
O:
0.0%
H:
5.64%
C:
5.15%
XNCR
|
$19.08
0.85%
0.84%
450K
|
Health Technology
|
-29.32%
|
O:
-0.33%
H:
1.52%
C:
1.34%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-14.12%
|
O:
0.18%
H:
0.41%
C:
0.02%
companies
active
renal
cell
treatment
market
Alkermes Publishes Investor Presentation Detailing Company's Transformation and Value Creation
Published:
2023-06-08
(Crawled : 11:00)
- investor.alkermes.com
JNJ
|
News
|
$144.77
0.22%
-0.01%
9.3M
|
Health Technology
|
-8.67%
|
O:
-0.01%
H:
1.21%
C:
1.11%
UTHR
|
$235.44
1.58%
1.55%
370K
|
Health Technology
|
6.64%
|
O:
0.37%
H:
2.61%
C:
2.27%
RARE
|
$44.11
4.25%
4.08%
890K
|
Health Technology
|
-14.88%
|
O:
-0.33%
H:
1.43%
C:
-0.14%
SRPT
|
$117.885
0.51%
0.48%
550K
|
Health Technology
|
-7.83%
|
O:
-0.4%
H:
1.32%
C:
-1.16%
SAGE
|
News
|
$12.585
-19.48%
-24.2%
4.3M
|
Health Technology
|
-77.76%
|
O:
-0.34%
H:
1.12%
C:
0.64%
PTCT
|
News
|
$25.19
-0.4%
-0.4%
670K
|
Health Technology
|
-42.27%
|
O:
-0.48%
H:
1.54%
C:
-1.87%
NBIX
M
|
$133.26
0.2%
0.2%
570K
|
Health Technology
|
42.95%
|
O:
0.0%
H:
1.27%
C:
0.89%
JAZZ
|
News
|
$107.15
-1.61%
-1.63%
590K
|
Health Technology
|
-16.67%
|
O:
-0.4%
H:
1.52%
C:
-0.33%
IRWD
|
$7.66
-2.92%
-3.0%
2.4M
|
Health Technology
|
-33.54%
|
O:
0.52%
H:
0.69%
C:
0.26%
IONS
|
$40.93
-1.47%
-1.49%
1.1M
|
Health Technology
|
0.89%
|
O:
-0.12%
H:
3.43%
C:
2.84%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-14.12%
|
O:
0.18%
H:
0.41%
C:
0.02%
EXEL
|
$22.875
0.24%
0.24%
2.8M
|
Health Technology
|
19.49%
|
O:
0.0%
H:
1.71%
C:
0.42%
BPMC
|
$88.395
2.68%
2.61%
730K
|
Health Technology
|
43.41%
|
O:
-0.9%
H:
1.07%
C:
-4.84%
ALNY
|
$145.23
-1.02%
-1.03%
500K
|
Health Technology
|
-22.85%
|
O:
0.03%
H:
1.32%
C:
0.11%
ALKS
|
News
|
$24.05
1.18%
1.16%
2.3M
|
Health Technology
|
-22.32%
|
O:
0.32%
H:
3.63%
C:
1.25%
ACAD
|
News
|
$17.2
0.7%
0.7%
1M
|
Health Technology
|
-30.13%
|
O:
-1.1%
H:
4.89%
C:
3.0%
presentation
Innovent Presents Phase 1 Clinical Data of IBI351 (KRASG12C Inhibitor) as Monotherapy for Metastatic Colorectal Cancer at the 2023 ASCO Annual Meeting
Published:
2023-06-06
(Crawled : 00:00)
- prnewswire.com
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
68.99%
|
O:
0.8%
H:
0.23%
C:
-1.06%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-9.59%
|
O:
0.94%
H:
0.27%
C:
0.02%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-15.47%
|
O:
0.45%
H:
0.14%
C:
-1.5%
ibi351
asco
cancer
meeting
Innovent and IASO Bio Updated Efficacy and Safety Clinical Data of Equecabtagene Autoleucel (BCMA CAR-T Cell Therapy) for Multiple Myeloma at the 2023 ASCO Annual Meeting
Published:
2023-06-06
(Crawled : 00:00)
- prnewswire.com
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-9.59%
|
O:
0.94%
H:
0.27%
C:
0.02%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-15.47%
|
O:
0.45%
H:
0.14%
C:
-1.5%
asco
cell
meeting
car-t
Innovent Presents Phase 1b Clinical Data of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2023 ASCO Annual Meeting
Published:
2023-06-05
(Crawled : 00:00)
- prnewswire.com
SNYNF
|
News
|
$92.116
-2.18%
2.3K
|
Health Technology
|
-8.08%
|
O:
0.4%
H:
0.0%
C:
0.0%
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
69.73%
|
O:
0.15%
H:
1.08%
C:
0.28%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-9.18%
|
O:
0.45%
H:
0.0%
C:
0.0%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-15.7%
|
O:
-0.29%
H:
0.88%
C:
0.02%
ibi110
asco
meeting
Innovent Updates Phase 1b Data of IBI939 (Anti-TIGIT Monoclonal Antibody) Combined with Sintilimab in Previously Untreated PD-L1-selected NSCLC at the 2023 ASCO Annual Meeting
Published:
2023-06-04
(Crawled : 00:20)
- prnewswire.com
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
Email alert
Add to watchlist
SNYNF
|
News
|
$92.116
-2.18%
2.3K
|
Health Technology
|
Email alert
Add to watchlist
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
Email alert
Add to watchlist
ibi939
asco
meeting
Innovent Announces the Second Breakthrough Therapy Designation by NMPA for Olverembatinib for the Treatment of Patients with SDH-Deficient GIST
Published:
2023-06-02
(Crawled : 00:20)
- prnewswire.com
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
Email alert
Add to watchlist
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
Email alert
Add to watchlist
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
Email alert
Add to watchlist
SNYNF
|
News
|
$92.116
-2.18%
2.3K
|
Health Technology
|
Email alert
Add to watchlist
treatment
designation
therapy
Innovent Enters into Clinical Trial Collaboration with Merck KGaA, Darmstadt, Germany Investigating Combination Therapy of IBI351 (KRASG12C Inhibitor) and Cetuximab (ERBITUX®)for KRASG12C-mutated NSCLC in China
Published:
2023-06-02
(Crawled : 00:00)
- prnewswire.com
SNYNF
|
News
|
$92.116
-2.18%
2.3K
|
Health Technology
|
-8.59%
|
O:
-0.56%
H:
0.0%
C:
0.0%
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
72.0%
|
O:
0.79%
H:
1.08%
C:
0.54%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-8.22%
|
O:
1.05%
H:
0.0%
C:
0.0%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-14.29%
|
O:
-0.02%
H:
1.79%
C:
1.69%
ibi351
erbitux
merck
germany
collaboration
trial
china
therapy
Alkermes Files Definitive Proxy Statement and Issues Letter to Shareholders Detailing Business Execution That Has Driven Strong Performance and Delivered Shareholder Value
Published:
2023-05-25
(Crawled : 21:00)
- investor.alkermes.com
JNJ
|
News
|
$144.77
0.22%
-0.01%
9.3M
|
Health Technology
|
-6.24%
|
O:
0.18%
H:
0.38%
C:
-0.22%
UTHR
|
$235.44
1.58%
1.55%
370K
|
Health Technology
|
10.92%
|
O:
0.0%
H:
0.84%
C:
-2.27%
RARE
|
$44.11
4.25%
4.08%
890K
|
Health Technology
|
-11.64%
|
O:
0.3%
H:
0.45%
C:
-0.48%
SRPT
|
$117.885
0.51%
0.48%
550K
|
Health Technology
|
-8.51%
|
O:
-0.01%
H:
0.64%
C:
-1.58%
SAGE
|
News
|
$12.585
-19.48%
-24.2%
4.3M
|
Health Technology
|
-74.43%
|
O:
0.43%
H:
2.19%
C:
1.76%
PTCT
|
News
|
$25.19
-0.4%
-0.4%
670K
|
Health Technology
|
-42.11%
|
O:
-0.48%
H:
1.78%
C:
-1.36%
NBIX
M
|
$133.26
0.2%
0.2%
570K
|
Health Technology
|
44.53%
|
O:
0.28%
H:
1.44%
C:
-1.32%
JAZZ
|
News
|
$107.15
-1.61%
-1.63%
590K
|
Health Technology
|
-16.03%
|
O:
-0.32%
H:
0.51%
C:
-0.98%
IRWD
|
$7.66
-2.92%
-3.0%
2.4M
|
Health Technology
|
-28.7%
|
O:
-0.19%
H:
2.05%
C:
0.93%
IONS
|
$40.93
-1.47%
-1.49%
1.1M
|
Health Technology
|
4.44%
|
O:
0.08%
H:
4.23%
C:
3.93%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-16.14%
|
O:
0.0%
H:
0.21%
C:
-0.46%
EXEL
|
$22.875
0.24%
0.24%
2.8M
|
Health Technology
|
20.99%
|
O:
-0.05%
H:
1.47%
C:
0.58%
BPMC
|
$88.395
2.68%
2.61%
730K
|
Health Technology
|
58.6%
|
O:
0.04%
H:
6.92%
C:
6.35%
ALNY
|
$145.23
-1.02%
-1.03%
500K
|
Health Technology
|
-21.12%
|
O:
0.27%
H:
1.27%
C:
0.94%
ALKS
|
News
|
$24.05
1.18%
1.16%
2.3M
|
Health Technology
|
-17.9%
|
O:
0.03%
H:
1.02%
C:
-0.24%
ACAD
|
News
|
$17.2
0.7%
0.7%
1M
|
Health Technology
|
-29.61%
|
O:
-0.25%
H:
1.68%
C:
1.6%
business
Incyte to Present at Upcoming Investor Conferences - May 23, 2023
Published:
2023-05-23
(Crawled : 13:00)
- biospace.com/
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-18.12%
|
O:
-0.05%
H:
2.49%
C:
1.12%
Innovent Announces Clinical Data of Multiple Trials Will be Presented at the 2023 ASCO and EHA Annual Meetings
Published:
2023-05-17
(Crawled : 00:00)
- prnewswire.com
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
71.94%
|
O:
0.49%
H:
0.03%
C:
-0.3%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-14.99%
|
O:
-0.73%
H:
0.0%
C:
0.0%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-18.52%
|
O:
-0.08%
H:
0.23%
C:
-0.15%
asco
trials
Innovent Receives NMPA Breakthrough Designation for IBI351 (KRASG12C Inhibitor) as Monotherapy for Previously Treated Advanced Colorectal Carcinoma
Published:
2023-05-15
(Crawled : 00:00)
- prnewswire.com
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
72.82%
|
O:
0.22%
H:
0.14%
C:
-0.2%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-14.75%
|
O:
0.38%
H:
0.0%
C:
0.0%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-19.24%
|
O:
0.34%
H:
1.13%
C:
1.07%
ibi351
designation
Innovent Announces Phase 2 Clinical Study of Higher dose 9 mg Mazdutide (IBI362) in Chinese Adults with Obesity Achieved the 24-Week Primary Endpoint
Published:
2023-05-11
(Crawled : 01:00)
- prnewswire.com
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
72.23%
|
O:
0.18%
H:
0.03%
C:
-0.26%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-14.77%
|
O:
-0.28%
H:
0.0%
C:
0.0%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-17.52%
|
O:
0.3%
H:
0.12%
C:
0.09%
ibi362
obesity
chinese
study
Syros Reports First Quarter 2023 Financial Results and Provides a Corporate Update
Published:
2023-05-10
(Crawled : 13:00)
- biospace.com/
SYRS
|
$5.105
-8.18%
-8.91%
130K
|
Health Technology
|
64.31%
|
O:
0.0%
H:
15.7%
C:
10.29%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-18.6%
|
O:
0.29%
H:
0.07%
C:
-1.6%
update
financial
results
The China NMPA Approves TYVYT® (sintilimab injection) in Combination with Bevacizumab and Chemotherapy in Patients with EGFR-mutated Non-squamous NSCLC who Progressed after EGFR-TKI Therapy
Published:
2023-05-10
(Crawled : 00:00)
- prnewswire.com
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
75.26%
|
O:
-0.54%
H:
2.89%
C:
2.31%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-16.26%
|
O:
-1.75%
H:
0.0%
C:
0.0%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-18.6%
|
O:
0.29%
H:
0.07%
C:
-1.6%
tyvyt
china
therapy
← Previous
1
2
3
4
5
6
7
8
9
10
…
22
23
Next →
Gainers vs Losers
56%
44%
Top 10 Gainers
INVO
|
$1.76
131.58%
56.82%
230M
|
Health Technology
SINT
|
$0.0365
59.39%
37.26%
470M
|
Health Technology
WISA
4
|
$9.19
50.66%
33.7%
65M
|
Electronic Technology
EDBL
|
News
|
$6.73
47.91%
32.39%
13M
|
GCTK
|
$0.715
36.27%
26.62%
640K
|
Manufacturing
TCON
|
$2.33
36.26%
26.61%
2M
|
Health Technology
TIRX
|
$0.48
6.43%
24.58%
4.8M
|
KZIA
|
$0.38
30.58%
23.42%
300K
|
Health Technology
VNDA
|
News
|
$5.23
29.14%
22.56%
24M
|
Health Technology
ATNF
|
$1.91
29.05%
22.51%
310K
|
Your saved searches
Save your searches and get alerts when important news are released.